a chemical tasked with transmitting signals in the brain to coordinate movement. Entacom Tablet (Entacapone 200mg) inhibits the enzyme catechol-O-methyltransferase (COMT)

What is a chemical tasked with transmitting signals in the brain to coordinate movement. Entacom Tablet (Entacapone 200mg) inhibits the enzyme catechol-O-methyltransferase (COMT)?

Entacom Tablet contains entacapone 200mg, a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), an enzyme that breaks down dopamine in the brain. In Parkinson’s disease, dopamine levels are low, leading to impaired movement control. By blocking COMT, Entacom helps prolong the effect of levodopa—a dopamine precursor—thereby improving motor function and reducing 'off' periods during treatment.

Key features

• Active Ingredient — Entacapone 200mg per tablet.
• Mechanism — Selective COMT enzyme inhibition.
• Usage — Adjunct to levodopa-carbidopa therapy.
• Dosage Form — Oral tablet for daily administration.
• Target Condition — Parkinson’s disease motor fluctuations.
• Sold By — HealthyRXS, with variable pricing.
• Availability — In stock, prescription required.

Who is a chemical tasked with transmitting signals in the brain to coordinate movement. Entacom Tablet (Entacapone 200mg) inhibits the enzyme catechol-O-methyltransferase (COMT) for?

This medication is intended for individuals diagnosed with Parkinson’s disease, particularly those experiencing end-of-dose 'wearing-off' phenomena while on levodopa therapy. It is prescribed to adults seeking improved mobility and reduced stiffness, tremors, and slowness of movement. Not suitable for patients with liver disease, pheochromocytoma, or those on MAO inhibitors.

How does a chemical tasked with transmitting signals in the brain to coordinate movement. Entacom Tablet (Entacapone 200mg) inhibits the enzyme catechol-O-methyltransferase (COMT) compare?

Compared to standard Parkinson’s treatments like levodopa alone, Entacom extends symptom control by preventing dopamine breakdown. Unlike tolcapone, another COMT inhibitor, it has a lower risk of hepatotoxicity, making it safer for long-term use. It does not replace dopamine but enhances existing therapy, offering a targeted approach without the risks associated with higher-dose levodopa regimens.